(Embargoed until Sunday, 14 September 2008, 15:30 CEST)
For patients with early stage breast cancer that has spread to the
lymph nodes, adding docetaxel into a sequential regimen of epirubicin
followed by cyclophosphamide, methotrexate and fluorouracil (CMF) reduces
the risk of recurrence and death, updated long-term results show. This
advantage comes at the cost of an increased, but manageable, toxicity,
Italian researchers report.
Pegylated liposomal doxorubicin beneficial in metastatic breast cancer
(Embargoed until Monday 15 September 2008, 12:30 CEST)
For women with metastatic breast cancer, treatment with an encapsulated
form of the drug doxorubicin offers a well-tolerated option for maintenance
therapy that delays progression and offers benefits in terms of survival,
new results show presented by Spanish researcher Emilio Alba.
Late breaking data: New drug substantially extends survival in pancreatic
(Embargoed until Tuesday, 16 September 2008, 10:00 CEST)
A new form of chemotherapy that destroys new blood vessels that grow
around tumours has produced excellent results in a phase II trial of
patients with inoperable pancreatic cancer, Prof. Matthias Lohr from the
Karolinska Institute reports.
Late breaking data: Gene marker indicates doubling of survival time in
advanced colorectal cancer treated with cetuximab
(Embargoed until Tuesday, 16 September 2008, 08:30 CEST)
Genetic testing can identify a group of patients with advanced
colorectal cancer who are likely to survive on average twice as long if
treated with the drug cetuximab, show results presented by Dr. Christos
Karapetis from Flinders University in Australia.
Drug shows promise in ovarian cancer
(Embargoed until Monday, 15 September 2008, 10:45 CEST)
An investigational drug that combats ovarian cancer b
|SOURCE ESMO European Society for Medical Oncology|
Copyright©2008 PR Newswire.
All rights reserved